Literature DB >> 2900198

Somatostatin receptors in normal and tumoral tissue.

J C Reubi1, S W Lamberts, R Maurer.   

Abstract

Somatostatin receptors have been visualized with autoradiography and characterised biochemically in various somatostatin target tissues, such as brain, pituitary, pancreas and gastrointestinal tract, where they are likely to mediate the somatostatin actions. With the same methods, somatostatin receptors have been detected also in tumors originating from somatostatin target tissues: high receptor incidence is found in GH-producing pituitary adenomas as well as in some hormone-producing gastrointestinal tumors. These tumors are often highly responsive to somatostatin analogs in vivo. Among brain tumors, meningiomas usually contain a high density of receptors, suggesting a novel function for somatostatin in the human meninges. Among other human tumors tested, prostate, ovarian and endometrial carcinomas were free of receptors whereas 3 out of 39 mammary tumors contained somatostatin receptors.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2900198     DOI: 10.1159/000180970

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  7 in total

1.  Expression cloning of a rat brain somatostatin receptor cDNA.

Authors:  F W Kluxen; C Bruns; H Lübbert
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

Review 2.  Unresolved surgical issues in the management of patients with Zollinger-Ellison syndrome.

Authors:  J A Norton; R T Jensen
Journal:  World J Surg       Date:  1991 Jan-Feb       Impact factor: 3.352

3.  Permeability of the murine blood-brain barrier to some octapeptide analogs of somatostatin.

Authors:  W A Banks; A V Schally; C M Barrera; M B Fasold; D A Durham; V J Csernus; K Groot; A J Kastin
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

4.  Follicle stimulating hormone-secreting pituitary adenoma: inappropriate secretion and effect of pulsatile luteinizing hormone releasing hormone analogue (buserelin) administration.

Authors:  S Damjanović; D Micić; V Popović; M Petakov; A Kendereski; M Sumarac; D Manojlović; J Mićić
Journal:  J Endocrinol Invest       Date:  1991-04       Impact factor: 4.256

Review 5.  Somatostatin, somatostatin receptors, and pancreatic cancer.

Authors:  Min Li; William E Fisher; Hee Joon Kim; Xiaoping Wang; Charles F Brunicardi; Changyi Chen; Qizhi Yao
Journal:  World J Surg       Date:  2005-03       Impact factor: 3.352

6.  Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone.

Authors:  M Bradette; M Delvaux; G Staumont; J Fioramonti; L Bueno; J Frexinos
Journal:  Dig Dis Sci       Date:  1994-06       Impact factor: 3.199

7.  Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours.

Authors:  S Angeletti; V D Corleto; O Schillaci; M Marignani; B Annibale; A Moretti; G Silecchia; F Scopinaro; N Basso; C Bordi; G Delle Fave
Journal:  Gut       Date:  1998-06       Impact factor: 23.059

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.